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Abstract
Purpose Rim lesions, characterised by a paramagnetic rim on susceptibility-based MRI, have been suggested to reflect 
chronic inflammatory demyelination in multiple sclerosis (MS) patients. Here, we assess, through susceptibility-weighted 
imaging (SWI), the prevalence, longitudinal volume evolution and clinical associations of rim lesions in subjects with early 
relapsing–remitting MS (RRMS).
Methods Subjects (n = 44) with recently diagnosed RRMS underwent 3 T MRI at baseline (M0) and 1 year (M12) as part 
of a multi-centre study. SWI was acquired at M12 using a 3D segmented gradient-echo echo-planar imaging sequence. Rim 
lesions identified on SWI were manually segmented on FLAIR images at both time points for volumetric analysis.
Results Twelve subjects (27%) had at least one rim lesion at M12. A linear mixed-effects model, with ‘subject’ as a random 
factor, revealed mixed evidence for the difference in longitudinal volume change between rim lesions and non-rim lesions 
(p = 0.0350 and p = 0.0556 for subjects with and without rim lesions, respectively). All 25 rim lesions identified showed 
T1-weighted hypointense signal. Subjects with and without rim lesions did not differ significantly with respect to age, disease 
duration or clinical measures of disability (p > 0.05).
Conclusion We demonstrate that rim lesions are detectable in early-stage RRMS on 3 T MRI across multiple centres, although 
their relationship to lesion enlargement is equivocal in this small cohort. Identification of SWI rims was subjective. Agreed 
criteria for defining rim lesions and their further validation as a biomarker of chronic inflammation are required for transla-
tion of SWI into routine MS clinical practice.
Keywords Multiple sclerosis · Magnetic resonance imaging · Susceptibility-weighted imaging · Rim lesions
Introduction
Multiple sclerosis (MS) is a chronic neurological condition 
affecting over 2 million individuals worldwide [1]. MS is 
an immune-mediated disease characterised by inflamma-
tion, demyelination, neurodegeneration and remyelination. 
Most patients initially diagnosed with relapsing–remitting 
MS (RRMS), the most common form of MS, experience 
two distinct clinical phases, reflecting a dominant role for 
distinct pathological processes. Inflammation drives activity 
during the relapsing–remitting stage, with neurodegenera-
tion being predominant in progressive MS characterised by 
accumulating disability [2].
Whilst the reference standard for pathological characteri-
sation is histological analysis of biopsy or, more commonly, 
autopsy material [3–5], recent progress in imaging raises 
the possibility of non-invasive and longitudinal measure-
ment and ‘pathological’ characterisation of lesions. For 
instance, susceptibility-based magnetic resonance imaging 
(MRI) provides support for the paramagnetic properties of 
certain MS lesions [6–8]. These lesions may be identified 
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on susceptibility-weighted imaging (SWI) by a hyperintense 
core surrounded by a partial or complete rim of hypointense 
signal. The high tissue susceptibility observed at the edge of 
rim lesions has been histologically shown to correspond to 
iron deposition and a high density of activated myeloid cells, 
suggesting the involvement of iron-laden macrophages/
microglia [9–11]. The origin of iron in myeloid cells is still 
unclear, although damage to myelin and oligodendrocytes 
may result in the release of iron into the interstitium and 
subsequent engulfment by macrophages and microglia [12].
Rim lesions have been found to coincide with regions 
of hypointensity on T1-weighted spin-echo sequences, also 
known as ‘T1 black holes’, as well as with hypointensity on 
fluid-attenuated inversion recovery (FLAIR), both of which 
are associated with substantial tissue damage [13, 14]. Rim 
lesions appear to experience significant growth over time 
compared with lesions without rims, supporting histological 
evidence that they could reflect a state of chronic inflam-
matory demyelination due to macrophage/microglial activ-
ity [10, 11]. Iron-laden rims are also rarely found around 
remyelinated plaques [10]. Against this background of com-
bined pathological and radiological evidence, rim lesions 
have been argued to represent a potential marker of chronic 
or low-level inflammation in MS. Rim lesions are also not 
present in ‘mimic’ conditions such as neuromyelitis optica 
spectrum disorder (NMOSD), Susac syndrome and cerebro-
vascular disease [15–20].
The clinical correlates of rim lesions are unclear, as they 
are observed in clinically isolated syndrome (CIS), radio-
logically isolated syndrome (RIS) as well as RRMS and pro-
gressive disease [21–23]. However, recent results suggest 
that non-gadolinium enhancing rim lesions, also known as 
‘chronic active lesions’, are linked to a more severe disease 
phenotype [11]. The majority of rim lesion studies in MS 
have been single-centre and focussed on later stage disease 
[23]. In this multi-centre study, we sought to evaluate the 
prevalence of rim lesions and their relationship with ‘T1-w 
hypointense lesions’ in recently diagnosed RRMS patients 
using SWI at 3 T.
Methods
Subjects
Subjects (n = 44) were recruited from a multi-centre pro-
spective observational cohort study for people recently diag-
nosed with RRMS. The inclusion criteria were as follows: 
diagnosis of RRMS according to 2010 McDonald criteria 
[24], within 6 months of diagnosis at baseline assessment 
(M0), age ≥ 18 years at baseline assessment, disease-modi-
fying therapy (DMT) not prescribed prior to baseline assess-
ment, no contraindication to MR brain imaging. Participants 
attend two clinic visits, approximately 12 months apart for 
clinical examinations, brain MR imaging and laboratory 
tests. SWI was carried out at the 1-year time point (M12).
Clinical assessment
Motor and cognitive disability of participants are assessed 
via various measures including the Expanded Disability Sta-
tus Scale (EDSS), the Timed 25-Foot Walk Test (T25FWT), 
the Paced Auditory Serial Addition Test (PASAT), the Sym-
bol Digit Modalities Test (SDMT) and the Multiple Sclero-
sis Functional Composite (MSFC) score. Plasma neurofila-
ment (NfL) levels are obtained from participants at M0 using 
a single-molecule ELISA. The assay is run on a 4-Plex "A" 
Kits Quanterix and Simoa SR-XTM benchtop instrument.
MRI acquisition
MRI was performed at three research sites on Prisma 3 T 
MRI systems (Siemens Healthcare, Erlangen, De) using 
either a 32-channel or 20-channel receive head coil and with 
a maximum gradient strength of 80 mT/m. The brain imag-
ing protocol for both timepoints (M0 and M12) includes 
3D volume T1-weighted, 2D axial PD/T2-weighted (dual 
echo), 3D volume FLAIR and 2D axial FLAIR sequences 
(please see Supplementary Table S1 for detailed acquisi-
tion parameters). SWI was acquired at M12; magnitude, 
phase and susceptibility-weighted images were acquired 
using a 3D segmented gradient-echo echo-planar imaging 
sequence (repetition time (TR)/echo time (TE) = 64/35 ms, 
flip angle = 10 degrees, voxel size = 0.65 mm isotropic, 
acquisition time = 7:08 m:ss) [25].
Data analysis
Identification of rim lesions
Following conversion of DICOM images to NIfTI format 
using the dcm2niix tool [26], rigid body registration (6 
degrees of freedom) of follow-up 2D FLAIR to SWI images 
was performed using the FMRIB’s Linear Image Registra-
tion Tool (FLIRT) software [27, 28]. Hyperintense white 
matter lesions (WMLs) were identified on registered 2D 
FLAIR and assessed in all three anatomical planes on corre-
sponding SWI images using ITK-SNAP Version 3.8.0 [29]. 
Rim lesions were defined as lesions that were hyperintense 
on FLAIR and were characterised on SWI by a hyperintense 
core partially or completely surrounded by a hypointense 
rim. Possible rim lesions were identified by one trained 
observer and reviewed by a senior neuroradiologist. SWI 
images were also independently assessed for rim lesions by 
a second neuroradiologist, after which the final rim lesion 
count for each subject was determined by consensus of all 
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three raters. Lesions with a minimum diameter of less than 
3 mm were deemed too small to be reliably assessed for the 
presence of a rim and were excluded. Lesions located near 
a high density of veins or considerable juxtacortical signal 
heterogeneity could not be reliably evaluated and were there-
fore not considered for inclusion.
Identification of ‘T1‑w hypointense lesions’ 
and ‘FLAIR‑hypointense core lesions’
After rim lesion identification, T1-weighted images were 
registered to SWI images. SWI rim lesions were assessed 
on corresponding registered T1-weighted and 2D FLAIR 
images and classified as ‘T1-w hypointense lesions’ and 
‘FLAIR-hypointense core lesions’, respectively. ‘T1-w 
hypointense lesions’ were defined as lesions that were 
hyperintense on FLAIR and corresponded to a hypointense 
region on T1-weighted images. ‘FLAIR-hypointense core 
lesions’ were defined as lesions hyperintense on FLAIR, 
but demonstrating regions of hypointensity or isointensity 
relative to extralesional white matter, typically in the lesion 
core. Unregistered T1-weighted images at follow-up were 
also assessed to determine the total ‘T1-w hypointense 
lesion’ count. Lesions with a minimum diameter of less than 
3 mm were excluded, as these could not be reliably assessed. 
The ‘T1-w hypointense lesion’ count was performed twice 
on 10 randomly selected subjects in order to calculate the 
intraclass correlation coefficient (ICC). T2-weighted WML 
volume was estimated on 3D FLAIR as a percentage of 
intracranial volume (ICV).
Longitudinal volume analysis
Individual rim lesions were manually segmented on unreg-
istered 3D FLAIR images at both time points, and volumes 
computed using ITK-SNAP Version 3.8.0 [29]. All rim 
lesions were included in the longitudinal volume analysis. 
Distinct non-confluent lesions without rims in (a) subjects 
with rim lesions and (b) subjects without rim lesions were 
chosen as controls. Where possible, an equal number of rim 
and non-rim lesions were selected in each subject to allow 
for within-participant variability. Lesions that were previ-
ously excluded as they could not be reliably assessed for the 
presence of a rim were not eligible to act as control. Manual 
segmentation was performed twice on 10 randomly selected 
lesions (either rim or non-rim lesion) in order to determine 
the ICC.
Statistical analysis
Study participants were first classified into those with rim 
lesions and those without rim lesions at follow-up. Differ-
ences between the two groups with respect to demographic 
and clinical characteristics were assessed via statistical tests 
such as the Mann–Whitney U test and Fisher’s exact test 
according to variable type. Adjustment for multiple compari-
sons was not performed for demographic and clinical com-
parisons due to the exploratory nature of the study, although 
exact uncorrected p-values are reported. The relationship 
between rim lesion count and both ‘T1-w hypointense 
lesion’ count and WML volume was assessed by Spearman’s 
correlation. Differences in lesion volume between baseline 
and follow-up were evaluated using the Kruskal–Wallis test, 
with post hoc multiple comparisons using Dunn’s test with 
Bonferroni adjustment. A linear mixed-effects model was 
used to assess differences in longitudinal volume change 
amongst lesion groups, with ‘lesion type’ as a fixed effect 
and ‘subject’ as a random effect. ICC estimates were cal-
culated based on a single rating, absolute agreement, and 
two-way mixed-effects model. All statistical analyses were 
performed using R Version 3.6.3.
Results
Demographic and clinical characteristics
Forty-four subjects were included, all of whom were 
diagnosed with RRMS (Table 1). Seventy-five percent of 
the cohort was female. Mean age at the time of SWI was 
42.6 years (SD = 12.8), while mean times from diagnosis 
and onset of symptoms to SWI were 494 days (SD = 67) 
and 1781 days (SD = 1840), respectively. Mean duration of 
follow-up was 415 days (SD = 50). Median follow-up and 
baseline EDSS scores were 3.0 (1.0–6.0) and 2.25 (0–6.0), 
respectively. Median scores at follow-up for other measures 
of clinical disability including T25FWT, PASAT, SDMT 
and MSFC are provided in Table 1. Twenty-eight out of 
42 subjects (data not available for two subjects) were on 
DMT at follow-up, with two subjects being on more than 
one drug. Mean baseline plasma NfL levels were 8.4 pg/mL 
(SD = 5.2). Individual subject characteristics are provided in 
Supplementary Table S2.
Rim lesions
Twelve subjects (27%) demonstrated at least one rim lesion. 
A total of 25 rim lesions were identified, with the rim lesion 
count per subject ranging from 1 to 3, except in one subject 
in which 8 rim lesions were identified (mean [SD] for rim 
lesion count = 0.6 [1.4]). Rim lesions were predominantly 
observed supratentorially, with only one infratentorial 
rim lesion being identified. Examples of SWI rim lesions 
and corresponding 2D FLAIR images are shown in Fig. 1. 
Although concordant results were obtained for 9 out of 12 
subjects with rim lesions following independent review by 
 Neuroradiology
1 3
the two groups of raters, discussion amongst all three raters 
was required to reach a consensus regarding the rim lesion 
count in the remaining 3 subjects.
‘T1‑w hypointense lesions’ and ‘FLAIR‑hypointense 
core lesions’
Assessment of registered T1-weighted images and SWI 
images revealed that all 25 rim lesions (100%) corresponded 
to ‘T1-w hypointense lesions’. Ten rim lesions (40%) could 
further be classified as ‘FLAIR-hypointense core lesions’ on 
FLAIR images. Figure 2 shows an example of a rim lesion 
that on T1-weighted image demonstrated hypointensity, and 
on 2D FLAIR appeared as a hyperintense lesion exhibiting 
intralesional isointensity. A total of 874 ‘T1-w hypointense 
lesions’ were observed in all 44 subjects (Mean [SD] for 
‘T1-w hypointense lesion’ count = 20 [18]). All subjects had 
at least one ‘T1-w hypointense lesion’ (Range = 2–116). Rim 
lesions constituted only a small proportion of total ‘T1-w 
hypointense lesions’ (2.9%). No significant correlation was 
observed between rim lesion count and ‘T1-w hypointense 
lesion’ count (Spearman’s rho = 0.271, p value = 0.0752). 
Estimated ICC with 95% confidence intervals for ‘T1-w 
hypointense lesion’ count was 0.989 (0.950–0.997). The 
correlation between rim lesion count and WML volume was 
non-significant (Spearman’s rho = 0.118, p value = 0.4474).
Assessing group differences
No significant differences were observed at M12 between 
subjects with rim lesions and subjects without rim lesions 
with regard to age, disease duration, DMT status, EDSS or 
any other measures of clinical disability including T25FWT, 
PASAT, SDMT or MSFC (Table 1). Baseline plasma NfL 
levels also did not differ between the two groups. Female 
subjects appeared to constitute a greater proportion of 
Table 1  Demographic and clinical characteristics of study cohort
a Two missing values
b Twelve missing values
c Two missing values; Two subjects on two different drugs
d One missing value
* Statistical testing performed using Mann–Whitney U test
** Statistical testing performed using Fisher’s exact test
All subjects Subjects without rim lesions Subjects with rim lesions p value
Count, No. (%) 44 (100) 32 (72.7) 12 (27.3) -
Age (years), mean ± SD (range) 42.6 ± 12.8 (22.0–68.3) 44.3 ± 12.5 (22.0–68.3) 37.9 ± 12.8 (23.2–57.9) 0.169*
Female, No. (%) 33 (75) 27 (84.4) 6 (50) 0.045**
Time from diagnosis to SWI (days), mean ± SD 
(range)a
494 ± 67 (382–648) 503 ± 70 (391–648) 473 ± 54.6 (382–541) 0.356*
Time from onset to SWI (days),
mean ± SD (range)b
1781 ± 1840 (588–9669) 1977 ± 2154 (588–9669) 1350 ± 732 (705–2676) 0.589*
Duration of follow-up (days)
mean ± SD (range)
415 ± 50 (363–532) 419 ± 54 (363–532) 403 ± 35 (367–470) 0.693*
Follow-up EDSS, median (range) 3.0 (1.0–6.0) 3.0 (1.0–6.0) 2.75 (1.0–6.0) 0.632*
Baseline EDSS, median (range) 2.25 (0–6.0) 2.25 (0–6.0) 2.25 (1.0–5.5) 0.850*
Change in EDSS, mean ± SD (range) 0.35 ± 0.94 (− 1.5–4.0) 0.25 ± 0.79 (-1.5–2.0) 0.5 ± 1.25 (− 1.0–4.0) 0.467*
T25FWT, median (range) 4.5 (3.5–12.1) 4.5 (3.5–8.1) 4.6 (3.9–12.1) 0.251*
PASAT, median (range) 47.0 (0–60.0) 45.5 (0–59.0) 51.5 (30.0–60.0) 0.126*
SDMT, median (range) 58.0 (26.0–75.0) 57.5 (26.0–72.0) 60.5 (28.0–75.0) 0.823*
MSFC, median (range) 0.31 (− 1.76–1.33) 0.32 (− 1.76–1.33) 0.35 (-1.62–0.83) 0.969*
DMT, No. (%)c 28 (66.7) 19 (61.3) 9 (81.8) 0.283**
Alemtuzumab 2 (4.8) 2 (6.5) 0 (0)
Azathioprine 2 (4.8) 2 (6.5) 0 (0)
Dimethyl fumarate 14 (33.3) 7 (22.6) 7 (63.6)
Glatiramer acetate 5 (11.9) 5 (16.1) 0 (0)
Interferon beta-1a 3 (7.1) 3 (9.7) 0 (0)
Other 4 (9.5) 2 (6.5) 2 (18.2)
Baseline plasma NfL levels (pg/mL), mean ± SD 
(range)d
8.4 ± 5.2 (2.6–24.1) 8.6 ± 5.5 (2.6–24.1) 8.0 ± 4.2 (4.2–16.6) 0.760*
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subjects without rim lesions than of subjects with rim 
lesions (p = 0.045).
Longitudinal volume analysis
Twenty-five rim lesions, 26 non-rim lesions in subjects 
with rim lesions and 26 non-rim lesions in subjects without 
rim lesions were selected for longitudinal volume analysis 
(please see Supplementary Table S3 for more information 
on lesion selection). Rim lesions were significantly larger 
than non-rim lesions both in subjects with and without rim 
lesions both at baseline (mean [SD]/mm3 = 489 [253], 152 
[108] and 203 [146], respectively; p < 0.001) and at follow-
up (mean [SD]/mm3 = 506 [263], 138 [102] and 165 [103], 
respectively; p < 0.001). Non-rim lesions in subjects with 
and without rim lesions were not significantly different in 
size both at baseline and follow-up (p = 0.806 and p = 0.810, 
respectively). Estimated ICC with 95% confidence inter-
vals for volume determination by manual segmentation was 
0.988 (0.954–0.997).
We found mixed evidence for the difference in 1-year per-
centage longitudinal volume change between rim lesions and 
non-rim lesions (p = 0.0350 and p = 0.0556 for subjects with 
and without rim lesions, respectively). Percentage changes 
in lesion volumes are shown in Fig. 3. We also arbitrar-
ily categorised lesions, taking into account the margin of 
error during manual segmentation, as shrinking (x <  − 5%), 
steady (− 5% < x < 5%) or enlarging (x > 5%). Although 
shrinking, steady and enlarging subtypes were observed 
in all three lesion groups, enlarging lesions constituted a 
Fig. 1  Rim lesions observed 
at 3 T. SWI and correspond-
ing FLAIR images showing 
representative examples of rim 
lesions (indicated by red arrow) 
in different brain locations 
including periventricular (a, d), 
juxtacortical (b, e) and infraten-
torial (c, f) regions
Fig. 2  T1 and FLAIR appear-
ance of an SWI rim lesion. All 
rim lesions observed in our MS 
cohort, including this white 
matter lesion (indicated by red 
arrow) exhibited T1 hypointen-
sity. The lesion shown above is 
one of ten rim lesions that on 
FLAIR also appeared hyper-
intense with a core isointense 
or in this case, hypointense, 




greater proportion of rim lesions (60%) compared to non-rim 
lesions (27% for both subjects with and without rim lesions). 
A breakdown of lesion groups into the different subtypes is 
available from the Supplementary Material.
Discussion
In this study involving a cohort of recently diagnosed sub-
jects with RRMS, we observed a rim lesion prevalence of 
27%, with 12 out of 44 subjects having at least one. This 
accords with other recently published data [23] and sug-
gests that rim lesions are a feature of early MS, although 
less common than in patients with longer disease durations. 
Our study adds to the growing body of literature on SWI at 
3 T [11, 22, 23, 30, 31] and furthermore demonstrates the 
feasibility of multi-centre acquisition, albeit using a single 
manufacturer MRI platform in this instance. Further studies 
across different manufacturer platforms will be necessary 
for validation in large cohort studies towards future clinical 
implementation.
Notably, all 25 of the rim lesions identified in our study 
corresponded to ‘T1-w hypointense lesions’. Rim lesions 
comprised only a very small proportion of the overall 
number of ‘T1-w hypointense lesions’, however, and no 
significant correlation was observed between rim lesion 
count and ‘T1-w hypointense lesion’ count. Pathological 
correlation studies have shown ‘T1-w hypointense lesions’ 
characterised on spin-echo sequences as ‘T1 black holes’ 
to be associated with substantial tissue damage character-
ised by oedema, demyelination and axonal loss [32, 33]. 
‘T1-w hypointense lesions’ detected on volumetric spoiled 
gradient-recalled echo (SPGR), as used in the current and a 
growing number of other studies, have been less well char-
acterised pathologically, but are likely to show similar cor-
relations with underlying parenchymal damage.
A smaller number of rim lesions corresponded to 
‘FLAIR-hypointense core lesions’, which have also been 
described in the literature [34], and are likely to repre-
sent a subset of ‘T1-w hypointense lesions’. Our data do 
not allow any firm conclusions to be drawn regarding the 
nature of these and their relationship to chronic low-grade 
inflammation.
Because of their apparent specificity for MS, the presence 
of rim lesions has been suggested as potentially useful in 
the radiological differential diagnosis of other neurological 
conditions whose imaging appearances may overlap with 
MS [15–20]. Although we have demonstrated their presence 
Fig. 3  Longitudinal lesion volume change. Boxplots comparing volume changes over 1 year across the three different lesion groups, namely, rim 
lesions (left), non-rim lesions in subjects with rim lesions (middle) and non-rim lesions in subjects without rim lesions (right)
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in early MS, the low prevalence would in practice limit diag-
nostic sensitivity.
In line with previous findings, we were unable to dem-
onstrate strong evidence for a difference in the 1-year longi-
tudinal volume evolution between rim lesions and non-rim 
lesions, [10, 13], although potential errors in our volumetric 
measurement due to manual segmentation of poorly defined 
individual lesions may limit the sensitivity of our analysis. 
We nevertheless observed that rim lesions were more com-
monly enlarging, in contrast to ‘shrinking’ non-rim lesions. 
Our finding of similar volume changes in non-rim lesions in 
subjects who had one or more rim lesions and those who had 
none may indicate a more localised inflammatory process in 
rim lesions.
A number of studies suggest that a subset of rim lesions 
may initially shrink [6, 10, 11]. While no clear relationship 
has been established between the presence of a paramagnetic 
rim and lesion growth measured over short intervals, recent 
findings suggest that differences in lesion volume evolution 
become more pronounced over longer time periods [10, 11]. 
Although it remains unclear whether rim lesions and slowly 
enlarging lesions define the same lesion subgroup, an over-
lap between the two is likely.
Our study focuses on patients with recently diagnosed 
RRMS, and the observation of overall shrinkage of WMLs 
may well reflect partial resolution of acutely swollen lesions 
over the year following the acute inflammatory episodes 
which originally lead to diagnosis. The early stage in dis-
ease course may also help to explain the lack of association 
observed between the presence of rim lesions and clinical 
disability, as substantial variation in disability between 
patients often only becomes apparent over several years. The 
lack of significant association detected between rim lesions 
and elevated plasma neurofilament levels may also be influ-
enced by the modest prevalence of both in early disease, and 
the confound that the two measures were made a year apart.
Several factors can confound the assessment of paramag-
netic phase rims, including high venous density, regions of 
juxtacortical signal heterogeneity and the presence of sus-
ceptibility or motion-related artefacts. While rims were more 
commonly observed across larger lesions, we were unable to 
assess hypointensity around the edge of smaller lesions reli-
ably, which may in part be due to lower signal-to-noise ratio 
and contrast resolution at 3 T compared with ultra-high field 
7 T. This challenge is compounded by the fact that lesions 
are sometimes only partially bordered by a rim of decreased 
signal on SWI. The difficulty in confidently classifying rim 
lesions is reflected in our limited inter-rater concordance 
in rim lesion count and accords with previous observations 
regarding the current lack of standardised methods for evalu-
ating the presence of a paramagnetic phase rim, and that 
familiarity with susceptibility-based MRI may be necessary 
for guiding rim lesion assessment [30].
Our study has several limitations. First, the low preva-
lence of rim lesions in our patient cohort meant that rela-
tively few lesions could be included in our analysis. A fur-
ther significant limitation is that contrast-enhanced images 
were not acquired; as a result, ‘chronic active lesions’ that 
have been defined on imaging as non-gadolinium enhanc-
ing lesions with a paramagnetic rim could not be identi-
fied in our study. Active inflammatory lesions could also 
not be evaluated. We further recognise that SWI was only 
performed at a single 1-year timepoint (M12); the longitu-
dinal evolution of the paramagnetic rim sign could therefore 
not be assessed and limits correlative measurements with 
neurofilament levels which were only sampled at baseline 
(M0). Future efforts will focus on collecting longitudinal 
SWI in the same cohort.
Conclusion
Various lines of evidence indicate that rim lesions identified 
with SWI may reflect chronic inflammation in MS patients. 
We have demonstrated that rim lesions are also a feature of 
subjects with early MS using a 3 T SWI in a multi-centre 
context, and our data suggest a possible relationship with 
lesion growth and shrinkage. The integration of SWI rim 
lesions in routine MS imaging practice will require further 
studies in larger cohorts across the disease course and con-
sensus on a standardised approach to their assessment.
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